{"id":1639,"date":"2019-11-07T22:58:39","date_gmt":"2019-11-07T22:58:39","guid":{"rendered":"https:\/\/tris.sambrownprojects.com\/tris-pharma-to-present-two-posters-for-amphetamine-extended-release-tablet-at-the-2019\/"},"modified":"2024-06-03T11:11:44","modified_gmt":"2024-06-03T10:11:44","slug":"tris-pharma-to-present-two-posters-for-amphetamine-extended-release-tablet-at-the-2019","status":"publish","type":"post","link":"https:\/\/www.trispharma.com\/tris-pharma-to-present-two-posters-for-amphetamine-extended-release-tablet-at-the-2019\/","title":{"rendered":"Tris Pharma to Present Two Posters for Amphetamine Extended-Release Tablet at the 2019"},"content":{"rendered":"

Published on November 07, 2019<\/p>\n

Neuroscience Education Institute (NEI) Congress<\/em><\/p>\n

MONMOUTH JUNCTION, NJ, November 7, 2019 \/ PRNewswire\/ – Tris Pharma, Inc. (“Tris”), a specialty pharmaceutical company with a robust portfolio of approved products and a late-stage pipeline of innovative product candidates for the treatment of Attention Deficit Hyperactivity Disorder and related disorders, today announced that it will present data in two new posters at the 15th Annual Neuroscience Education Institute Congress taking place in Colorado Springs, CO, November 7 to 10, 2019.\u00a0 Amphetamine extended-release tablet is an investigational agent and is not currently approved for use in any country.<\/p>\n

Tris will be presenting new pharmacokinetics and palatability assessment data from a recently-completed study on amphetamine extended-release tablets. The titles of the posters, to be presented on November 9th, are:<\/p>\n